Evidence map›Paper›PMID 25474108›Full record

ArticlePloS one2014

Crushed and injected buprenorphine tablets: characteristics of princeps and generic solutions.

Régis Bouquié, Laura Wainstein, Paul Pilet, Jean-Marie Mussini, Guillaume Deslandes, Johann Clouet, Eric Dailly, Pascale Jolliet, Caroline Victorri-Vigneau

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.5field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Livedoid Dermatitis Treated With Nifedipine.Journal of investigative medicine high impact case reports
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Régis BouquiéService de Pharmacologie Clinique, Centre Hospitalier Universitaire de Nantes, Nantes, France; EA 4275 Biostatistique, Pharmacoépidémiologie et Mesures Subjectives en Santé, Université de Nantes, Nantes, France.
Laura WainsteinService de Pharmacologie Clinique, Centre Hospitalier Universitaire de Nantes, Nantes, France.
Paul PiletINSERM (Institut National de la Santé et de la Recherche Médicale), UMR (Unité Mixte de Recherche) 791, Laboratoire d'Ingénierie Ostéo-Articulaire et Dentaire (LIOAD), Université de Nantes, Nantes, France; Centre Hospitalier Universitaire de Nantes, Pôle Hospitalo-Universitaire 4, Nantes, France.
Jean-Marie MussiniLaboratoire d'Anatomie Pathologique, Centre Hospitalier Universitaire de Nantes, Nantes, France.
Guillaume DeslandesService de Pharmacologie Clinique, Centre Hospitalier Universitaire de Nantes, Nantes, France.
Johann ClouetInstitut National de la Santé et de la Recherche Médicale (INSERM) Unité Mixte de Recherche en Santé (UMRS) 791, Laboratoire d'Ingénierie Ostéo-Articulaire et Dentaire (LIOAD), Université de Nantes, Nantes, France; Centre Hospitalier Universitaire Nantes, Pôle Hospitalo-Universitaire (PHU) 7, Pharmacie Centrale, Nantes, France.
Eric DaillyClinical Pharmacology, Service de Pharmacologie Clinique, Centre Hospitalier Universitaire de Nantes, Nantes, France; EA 3826 Thérapeutiques Cliniques et Expérimentales des Infections, Université de Nantes, Nantes, France.
Pascale JollietEA 4275 Biostatistique, Pharmacoépidémiologie et Mesures Subjectives en Santé, Université de Nantes, Nantes, France; Clinical Pharmacology, Service de Pharmacologie Clinique, Centre Hospitalier Universitaire de Nantes, Nantes, France.
Caroline Victorri-VigneauEA 4275 Biostatistique, Pharmacoépidémiologie et Mesures Subjectives en Santé, Université de Nantes, Nantes, France; Pharmacology, Service de Pharmacologie Clinique, Centre Hospitalier Universitaire de Nantes, Nantes, France.
Centre Hospitalier Universitaire de Nantes · FRLe Laboratoire d'Ingénierie Ostéo-Articulaire et Dentaire · FRNantes Université · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Self-injection of high-dose buprenorphine is responsible for well-described complications. In 2011, we have been alerted by unusual but serious cutaneous complication among injection buprenorphine users. A prospective data collection identified 30 cases of necrotic cutaneous lesions after injection of filtered buprenorphine solution, among which 25 cases occurred following injection of buprenorphine generics. The main goal of our study was to put forward particularities that could explain the cutaneous complications, by qualitatively and quantitatively confronting particles present in Subutex and generics solutions. We used the same protocol that injected-buprenorphine users: generic or subutex tablets were crushed in sterile water and filtered through 2 filters commonly used (cotton-pad and sterifilt). Solutions were analyzed by laser granulometry, flow cytometry and scanning electron microscopy. We have highlighted the wide variation of the quantity and the size of the particles present in solution between the two drugs after cotton-pad filtration. The proportion of particles <10 µm is systematically higher in the generic solutions than with Subutex. All of the insoluble particles found in generic solutions contain silica, whereas non- organic element was to be identified in the insoluble particles of Subutex. One skin biopsy obtained from one patient who developed a necrotic lesion after intravenous injection of filtrated solution of buprenorphine generic, shows non-organic elements. Identification of particles in situ enables us to confirm the presence of silica in the biopsy. Actually the monitoring of patient receiving generic of buprenorphine must be strengthened.

Indexed as

Analgesics, OpioidBuprenorphineDermatitisDrugs, GenericFlow CytometryHumansInjections, SubcutaneousLasersMicroscopy, Electron, ScanningParticle SizeSkinSolutionsSubstance-Related DisordersTabletsAnalgesics, OpioidBuprenorphineDrugs, GenericSolutionsTablets

Identifiers

PMID25474108
PMCPMC4256378
OpenAlexW2013752223

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.